Navigation Links
London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions

LONDON, Jan. 26 /PRNewswire/ -- Double Helix Consulting US (DHC US), headed by Andrew M. Baker, President, joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry as well as strong commercial, governmental and academic links, who provide customer-centric market access strategies to clients in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

  • Product value message development and testing
  • Commercial assessment
  • Lifecycle planning
  • Development program and clinical trial planning
  • Managed markets strategy
  • Pharmacoeconomic evaluation and health technology assessment (HTA)
  • Payer and provider insight evaluation and influence planning
  • Pricing and reimbursement strategy, negotiation simulation, and training
  • Environmental scenario planning on key issues such as HTA decision intelligence, formulary design, utilization management strategies, policy reform, value-based benefit design, pay-for-performance, and healthcare quality measurement and accreditation
  • Market access training

Speaking about the new business, Drew commented "Double Helix Consulting US offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client- and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies."

Based in the greater New York area, Double Helix Consulting US joins Double Helix Consulting's London office in providing market access services to clients around the world.

Drew Baker has over 20 years' experience operating in and consulting to the global biopharmaceutical and healthcare industries. He has led initiatives in commercial opportunity assessment, lifecycle management, strategic planning, global pricing and reimbursement, and value-based marketing. Before joining Double Helix, Drew spent 14 years with Pfizer and was a founding member of the company's Outcomes Research function. He also was with Merck's public policy group and spent six years in biopharmaceutical consulting. Drew has published and presented extensively in the areas of product value estimation, healthcare quality and health policy. He holds an MBA from Duke University, a Master of Public Affairs from Princeton, and a BA in economic policy and BS in communications from Syracuse University.

Commenting on the new venture, Dr Wayne Phillips, CEO of parent company Double Helix Group said "The establishment of Double Helix Consulting US is a further extension of our core business and continues our overall expansion and development program for 2009 and beyond."



SOURCE Double Helix Consulting US
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
2. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
3. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
4. Farmers Across the U.S. Realize Double-Digit Yield Advantage From DEKALB(R) Corn Seeds With Triple-Stacked Traits
5. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
6. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
7. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
10. Adoption of Spinal Nonfusion Technologies Doubled in One Year
11. Microtest Labs Doubles Microbial Identification, Analytical Services
Post Your Comments:
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)...  Connected health pioneer, Joseph C. Kvedar , ... health and wellness, and the business opportunities that arise ... Internet of Healthy Things . Long before health ... Dr. Kvedar, vice president, Connected Health, Partners HealthCare, was ... care from the hospital or doctor,s office into the ...
Breaking Biology News(10 mins):